Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical
recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide …

Abstract Purpose/background [18 F] fluoroethylcholine (18 FECH) has been shown to be a
valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is …

Glu-NH-CO-NH-Lys-(Ahx)-[68Ga (HBED-CC)](68Ga-PSMA-11) is a PET tracer that can
detect prostate cancer relapses and metastases by binding to the extracellular domain of …

Objective 18 F-labeled prostate-specific membrane antigen (PSMA) ligand,[18 F] PSMA-
1007, has the benefit of a higher synthetic yield and minimal excretion in the urine. High …

Purpose The purpose of our study was to assess 18 F–DCFBC PET/CT, a PSMA targeted
PET agent, for lesion detection and clinical management of biochemical relapse in prostate …

Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as
recurrence localization guides subsequent therapies. The use of PET with prostate-specific …

18F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used
in preference to 68Ga-PSMA-11 for restaging biochemical recurrence (BCR) of prostate …

Purpose We studied the usefulness of 68 Ga-prostate-specific membrane antigen (PSMA)
PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence …

Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in
patients with prostate cancer. We aim to better characterize the impact of 68Ga-PSMA-11 …

Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-
specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients …